Asia’s Drug Policy at a Crossroads in 2026: ASEAN Review, Accountability Signals, and the Battle Between Health and Enforcement
The Diplomat, citing an IDPC decade review, describes Asia’s drug policy landscape as split between selective reforms and continued enforcement-heavy approaches with significant human impacts. The outlook for 2026 hinges on whether ASEAN institutions translate human-rights discussions and work-plan reviews into evidence-based policy changes supported by adequately funded civil society participation.